Table 4.

Summary of solicited AEs (immunogenicity and reactogenicity cohort) – phase 3 (safety population).

	First dose		Second dose
	SII-NVX-CoV2373 (N = 343) n (%) [E]	NVX-CoV2373 (N = 115) n (%) [E]	SII-NVX-CoV2373 (N = 343) n (%) [E]	NVX-CoV2373 (N = 115) n (%) [E]
Participants with at Least One Solicited Adverse Event	137 (39.9) [328]	35 (30.4) [86]	171 (50.1) [495]	54 (48.6) [143]
Participants with at Least One Local Solicited AE	94 (27.4) [153]	28 (24.3) [44]	116 (34.0) [184]	28 (25.2) [34]
Injection Site Pain	82 (23.9) [82]	28 (24.3) [28]	109 (32.0) [109]	26 (23.4) [26]
Injection Site Tenderness	34 (9.9) [34]	8 (7.0) [8]	39 (11.4) [39]	7 (6.3) [7]
Injection Site Swelling	15 (4.4) [15]	4 (3.5) [4]	13 (3.8) [13]	0
Injection Site Erythema	12 (3.5) [12]	3 (2.6) [3]	12 (3.5) [12]	0
Injection Site Induration	10 (2.9) [10]	1 (0.9) [1]	11 (3.2) [11]	1 (0.9) [1]
Participants with at Least One Systemic Solicited AE	91 (26.5) [175]	21 (18.3) [42]	145 (42.5) [311]	49 (44.1) [109]
Headache	54 (15.7) [54]	8 (7.0) [8]	68 (19.9) [68]	28 (25.2) [28]
Fatigue	30 (8.7) [30]	14 (12.2) [14]	61 (17.9) [61]	21 (18.9) [21]
Myalgia	29 (8.5) [29]	8 (7.0) [8]	54 (15.8) [54]	13 (11.7) [13]
Malaise	23 (6.7) [23]	2 (1.7) [2]	32 (9.4) [32]	8 (7.2) [8]
Arthralgia	15 (4.4) [15]	5 (4.3) [5]	34 (10.0) [34]	13 (11.7) [13]
Fever	12 (3.5) [12]	3 (2.6) [3]	49 (14.4) [49]	20 (18.0) [20]
Nausea	7 (2.0) [7]	1 (0.9) [1]	9 (2.6) [9]	3 (2.7) [3]
Vomiting	5 (1.5) [5]	1 (0.9) [1]	4 (1.2) [4]	3 (2.7) [3]